Futura Medical and Haleon partner to commercialise Eroxon gel in US

2023-07-17

·Pharmaceutical Technology

上市批准引进/卖出

Futura Medical and Haleon partner to commercialise Eroxon gel in US

Preview

来源: Pharmaceutical Technology

Robert Barrie

Preview

来源: Pharmaceutical Technology

MED3000 (marketed as Eroxon in the UK) became the first erectile dysfunction gel available to patients in the US without the need for a doctor’s prescription following FDA approval in June. Image credit: Shutterstock/Gorodenkoff.

UK-based Futura Medical has signed a deal with healthcare company Haleon to commercialise its over-the-counter (OTC) erectile dysfunction gel, Eroxon, in the US.

Eroxon, also known as MED3000, became the first erectile dysfunction gel available to patients in the US without the need for a doctor’s prescription following approval from the US Food and Drug Administration (FDA) last month.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsInnovation in Pharmaceuticals: Cyclosporin derivatives GlobalData

Preview

来源: Pharmaceutical Technology

ReportsInnovation in Pharmaceuticals: Pancreatic extract-based compositions GlobalData

View allCompanies IntelligencePfizer IncGSK plcHaleon PlcFutura Medical PlcGlaxoSmithKline KKView all

Haleon, which spun out from GlaxoSmithKline (GSK) last year, will now be responsible for the rollout of Eroxon in the US – overseeing regulatory, development, marketing, and commercialisation progress for the treatment.

In exchange, Futura will retain royalty payments on sales of the gel and receive an upfront payment of $4m. The sexual health pharmaceutical company is also in line to receive commercial and sales milestone payments up to a potential $45m.

Shares in Futura rose 12% at market open on Monday 17 July compared to the pre-announcement market close (14 July).

Futura’s gel, which is already available in the UK and Belgium, is directly applied to the glans of the penis and stimulates nerve sensors by a cooling and recovery warming effect. The gel is topical glyceryl trinitrate (GTN) delivered using the company’s DeraSys platform, which includes chemicals that help permeation through the skin. However, as the treatment itself works without a chemical reaction, it is classed as a medical device. The cooling creates a natural release of nitric oxide from the absorbed GTN, which leads to vasodilation in the penile arteries.

PDE5 inhibitors such as sildenafil, known by the brand name Viagra and marketed by Pfizer, and tadalafil, which is marketed by Eli Lilly as Cialis – both of which have generic equivalents available – dominate the market share for erectile dysfunction treatment, although they can take 30 to 60 minutes to kick in and require a prescription.

Eroxon’s evaporative mode of action, which leads to smooth muscle relaxation, means an erection is possible within ten minutes, according to Futura.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构